Baseline characteristics and survival outcomes of patients in the entire St Jude data set, the St Jude training and validation data sets, and the MSKCC data set
| Characteristic . | St Jude full cohort (N = 738) . | St Jude training cohort (n = 517) . | St Jude internal validation cohort (n = 221) . | MSKCC external validation cohort (N = 218) . |
|---|---|---|---|---|
| Transplantation period | ||||
| 2000-2004 | 183 (25%) | 125 (24%) | 58 (26%) | |
| 2005-2009 | 179 (24%) | 118 (23%) | 61 (28%) | |
| 2010-2014 | 181 (25%) | 133 (26%) | 48 (22%) | 91 (42%) |
| 2015-2020 | 195 (26%) | 141 (27%) | 54 (24%) | 127 (58%) |
| Recipient characteristics | ||||
| Time from diagnosis to allo-HCT, d | 222 (122-688) | 218 (120-681) | 225 (127-748) | 365 (0-822) |
| Unknown | 50 | |||
| Recipient age at allo-HCT, y | 9.8 (3.9-15.0) | 10.0 (4.0-15.0) | 9.5 (3.6-14.7) | 10 (3-15) |
| Recipient sex | ||||
| Female | 303 (41%) | 209 (40%) | 94 (43%) | 83 (38%) |
| Male | 435 (59%) | 308 (60%) | 127 (57%) | 135 (62%) |
| Recipient race | ||||
| Black | 138 (19%) | 100 (19%) | 38 (17%) | 38 (18%) |
| White | 517 (70%) | 361 (70%) | 156 (71%) | 130 (63%) |
| Other | 82 (11%) | 56 (11%) | 26 (12%) | 38 (18%) |
| Unknown | 1 | 0 | 1 | 12 |
| Recipient ethnicity | ||||
| Hispanic or Latino | 140 (19%) | 104 (20%) | 36 (16%) | 40 (19%) |
| Not Hispanic or Latino | 593 (81%) | 408 (80%) | 185 (84%) | 171 (81%) |
| Unknown | 5 | 5 | 0 | 7 |
| Donor characteristics | ||||
| Donor sex | ||||
| Female | 332 (47%) | 237 (48%) | 95 (45%) | 43 (50%) |
| Male | 370 (53%) | 256 (52%) | 114 (55%) | 43 (50%) |
| Unknown | 36 | 24 | 12 | 132 |
| Donor-recipient sex | ||||
| Female-female | 146 (21%) | 96 (19%) | 50 (24%) | 16 (19%) |
| Male-male | 225 (32%) | 151 (31%) | 74 (35%) | 27 (31%) |
| Female-male | 145 (21%) | 105 (21%) | 40 (19%) | 16 (19%) |
| Male-female | 186 (26%) | 141 (29%) | 45 (22%) | 27 (31%) |
| Unknown | 36 | 24 | 12 | 132 |
| Donor-recipient relatedness | ||||
| Matched related | 125 (27%) | 82 (25%) | 43 (30%) | 64 (29%) |
| Matched unrelated | 144 (31%) | 101 (31%) | 43 (30%) | 72 (33%) |
| Mismatched related | 172 (37%) | 127 (39%) | 45 (31%) | 26 (12%) |
| Mismatched unrelated | 30 (6.4%) | 18 (5.5%) | 12 (8.4%) | 56 (26%) |
| Unknown | 267 | 189 | 78 | |
| Disease characteristics | ||||
| Diagnosis | ||||
| ALL | 224 (30%) | 156 (30%) | 68 (31%) | 62 (28%) |
| AML | 246 (33%) | 183 (35%) | 63 (29%) | 52 (24%) |
| CML | 30 (4.1%) | 22 (4.3%) | 8 (3.6%) | 4 (1.8%) |
| Myelodysplastic syndrome | 35 (4.7%) | 22 (4.3%) | 13 (5.9%) | 13 (6.0%) |
| Other leukemias | 14 (1.9%) | 10 (1.9%) | 4 (1.8%) | 7 (3.2%) |
| Lymphoma | 24 (3.3%) | 12 (2.3%) | 12 (5.4%) | 11 (5.0%) |
| Aplastic anemia | 51 (6.9%) | 38 (7.4%) | 13 (5.9%) | 15 (6.9%) |
| Sickle cell anemia | 27 (3.7%) | 18 (3.5%) | 9 (4.1%) | 3 (1.4%) |
| Other nonmalignant disorder | 87 (12%) | 56 (11%) | 31 (14%) | 51 (23%) |
| Disease status at allo-HCT | ||||
| Active (malignant) | 109 (18%) | 71 (17%) | 38 (21%) | 16 (7.3%) |
| Active (nonmalignant) | 165 (28%) | 112 (27%) | 53 (30%) | 69 (32%) |
| Remission (malignant) | 324 (54%) | 238 (57%) | 86 (49%) | 133 (61%) |
| Unknown | 140 | 96 | 44 | |
| Transplant characteristics | ||||
| Preparative regimen | ||||
| Myeloablative | 345 (67%) | 245 (68%) | 100 (66%) | 192 (88%) |
| Reduced intensity | 140 (27%) | 99 (28%) | 41 (27%) | 7 (3.2%) |
| Nonmyeloablative | 27 (5.3%) | 16 (4.4%) | 11 (7.2%) | 19 (8.7%) |
| Unknown | 226 | 157 | 69 | |
| Product type | ||||
| Marrow | 447 (61%) | 313 (61%) | 134 (61%) | 85 (39%) |
| PBSC | 291 (39%) | 204 (39%) | 87 (39%) | 133 (61%) |
| Mortality outcomes | ||||
| Deaths by 100 d after allo-HCT | 60 (8.1%) | 42 (8.1%) | 18 (8.1%) | 8 (3.7%) |
| Deaths by 1 y after allo-HCT | 187 (25%) | 121 (23%) | 66 (30%) | 25 (11%) |
| Deaths by 2 y after allo-HCT | 233 (32%) | 154 (30%) | 79 (36%) | 43 (20%) |
| Characteristic . | St Jude full cohort (N = 738) . | St Jude training cohort (n = 517) . | St Jude internal validation cohort (n = 221) . | MSKCC external validation cohort (N = 218) . |
|---|---|---|---|---|
| Transplantation period | ||||
| 2000-2004 | 183 (25%) | 125 (24%) | 58 (26%) | |
| 2005-2009 | 179 (24%) | 118 (23%) | 61 (28%) | |
| 2010-2014 | 181 (25%) | 133 (26%) | 48 (22%) | 91 (42%) |
| 2015-2020 | 195 (26%) | 141 (27%) | 54 (24%) | 127 (58%) |
| Recipient characteristics | ||||
| Time from diagnosis to allo-HCT, d | 222 (122-688) | 218 (120-681) | 225 (127-748) | 365 (0-822) |
| Unknown | 50 | |||
| Recipient age at allo-HCT, y | 9.8 (3.9-15.0) | 10.0 (4.0-15.0) | 9.5 (3.6-14.7) | 10 (3-15) |
| Recipient sex | ||||
| Female | 303 (41%) | 209 (40%) | 94 (43%) | 83 (38%) |
| Male | 435 (59%) | 308 (60%) | 127 (57%) | 135 (62%) |
| Recipient race | ||||
| Black | 138 (19%) | 100 (19%) | 38 (17%) | 38 (18%) |
| White | 517 (70%) | 361 (70%) | 156 (71%) | 130 (63%) |
| Other | 82 (11%) | 56 (11%) | 26 (12%) | 38 (18%) |
| Unknown | 1 | 0 | 1 | 12 |
| Recipient ethnicity | ||||
| Hispanic or Latino | 140 (19%) | 104 (20%) | 36 (16%) | 40 (19%) |
| Not Hispanic or Latino | 593 (81%) | 408 (80%) | 185 (84%) | 171 (81%) |
| Unknown | 5 | 5 | 0 | 7 |
| Donor characteristics | ||||
| Donor sex | ||||
| Female | 332 (47%) | 237 (48%) | 95 (45%) | 43 (50%) |
| Male | 370 (53%) | 256 (52%) | 114 (55%) | 43 (50%) |
| Unknown | 36 | 24 | 12 | 132 |
| Donor-recipient sex | ||||
| Female-female | 146 (21%) | 96 (19%) | 50 (24%) | 16 (19%) |
| Male-male | 225 (32%) | 151 (31%) | 74 (35%) | 27 (31%) |
| Female-male | 145 (21%) | 105 (21%) | 40 (19%) | 16 (19%) |
| Male-female | 186 (26%) | 141 (29%) | 45 (22%) | 27 (31%) |
| Unknown | 36 | 24 | 12 | 132 |
| Donor-recipient relatedness | ||||
| Matched related | 125 (27%) | 82 (25%) | 43 (30%) | 64 (29%) |
| Matched unrelated | 144 (31%) | 101 (31%) | 43 (30%) | 72 (33%) |
| Mismatched related | 172 (37%) | 127 (39%) | 45 (31%) | 26 (12%) |
| Mismatched unrelated | 30 (6.4%) | 18 (5.5%) | 12 (8.4%) | 56 (26%) |
| Unknown | 267 | 189 | 78 | |
| Disease characteristics | ||||
| Diagnosis | ||||
| ALL | 224 (30%) | 156 (30%) | 68 (31%) | 62 (28%) |
| AML | 246 (33%) | 183 (35%) | 63 (29%) | 52 (24%) |
| CML | 30 (4.1%) | 22 (4.3%) | 8 (3.6%) | 4 (1.8%) |
| Myelodysplastic syndrome | 35 (4.7%) | 22 (4.3%) | 13 (5.9%) | 13 (6.0%) |
| Other leukemias | 14 (1.9%) | 10 (1.9%) | 4 (1.8%) | 7 (3.2%) |
| Lymphoma | 24 (3.3%) | 12 (2.3%) | 12 (5.4%) | 11 (5.0%) |
| Aplastic anemia | 51 (6.9%) | 38 (7.4%) | 13 (5.9%) | 15 (6.9%) |
| Sickle cell anemia | 27 (3.7%) | 18 (3.5%) | 9 (4.1%) | 3 (1.4%) |
| Other nonmalignant disorder | 87 (12%) | 56 (11%) | 31 (14%) | 51 (23%) |
| Disease status at allo-HCT | ||||
| Active (malignant) | 109 (18%) | 71 (17%) | 38 (21%) | 16 (7.3%) |
| Active (nonmalignant) | 165 (28%) | 112 (27%) | 53 (30%) | 69 (32%) |
| Remission (malignant) | 324 (54%) | 238 (57%) | 86 (49%) | 133 (61%) |
| Unknown | 140 | 96 | 44 | |
| Transplant characteristics | ||||
| Preparative regimen | ||||
| Myeloablative | 345 (67%) | 245 (68%) | 100 (66%) | 192 (88%) |
| Reduced intensity | 140 (27%) | 99 (28%) | 41 (27%) | 7 (3.2%) |
| Nonmyeloablative | 27 (5.3%) | 16 (4.4%) | 11 (7.2%) | 19 (8.7%) |
| Unknown | 226 | 157 | 69 | |
| Product type | ||||
| Marrow | 447 (61%) | 313 (61%) | 134 (61%) | 85 (39%) |
| PBSC | 291 (39%) | 204 (39%) | 87 (39%) | 133 (61%) |
| Mortality outcomes | ||||
| Deaths by 100 d after allo-HCT | 60 (8.1%) | 42 (8.1%) | 18 (8.1%) | 8 (3.7%) |
| Deaths by 1 y after allo-HCT | 187 (25%) | 121 (23%) | 66 (30%) | 25 (11%) |
| Deaths by 2 y after allo-HCT | 233 (32%) | 154 (30%) | 79 (36%) | 43 (20%) |
For categorical variables, n (%) is shown; for numerical variable, median (interquartile range) is shown.
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; PBSC, peripheral blood stem cell.